Clinical Research Directory
Browse clinical research sites, groups, and studies.
Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014
Sponsor: AHS Cancer Control Alberta
Summary
Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January 2010 and April 30, 2014. Efficacy, safety, and other relevant data will be collected to support a separate clinical trial application.
Key Details
Gender
All
Age Range
14 Years - 90 Years
Study Type
OBSERVATIONAL
Enrollment
115
Start Date
2012-08
Completion Date
2027-12
Last Updated
2026-11-03
Healthy Volunteers
No
Conditions
Interventions
Lu-177 DOTA-TATE
The regimen used for therapy for patients treated under SAP was a standard dose of 5.55 GBq Lu-177 DOTA-TATE every 10-12 weeks for 4 treatments, then every 6 months as maintenance treatment.
Locations (1)
Cross Cancer Institute
Edmonton, Alberta, Canada